The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch
Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being tested, as Gilgamesh Pharmaceuticals moves to challenge Enveric’s patent claims, just weeks after AbbVie announced its $1.2 billion acquisition of Gilgamesh’s lead compound, Bretisilocin (GM-2505). The post The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch appeared first on Microdose.
External link. We are not responsible for the content.
Read more ↗More From Microdose (industry)
AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy
In a development that could ripple across the fast evolving neuroplastogen sector, Enveric Biosciences announced that...
Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy
A new data release from Enveric Biosciences is sharpening the scientific debate at the heart of psychedelic drug deve...
Two New Studies Are Rewriting the Rules of Psychedelic Drug Development
For much of the last decade, psychedelic medicine has been driven by clinical outcomes first and mechanistic explanat...
Latest News
Comment perfectionner la préparation de son trip ?
La préparation d’un voyage est un processus à la fois intérieur et extérieur – qui consiste à aligner l’intention, l’...
Authors of Largest Microdosing Study Suggest Benefits Limited To Dosing Day
Recent research surveying 1,435 microdosers suggests that microdosing’s duration of effect might be more like that of...
The FDA is changing the drug approval process; In a Senate hearing, Surgeon General nominee Casey Means was asked about psychedelics use
Plus: RAND survey shows that nearly a quarter of U.S. adults support legal use of psilocybin mushrooms; Reunion Neuro...
Psilocybin for OCD: Terence Ching on Lessons from Yale’s Randomised Trials
In this conversation with Psychedelic Alpha’s Josh Hardman, Dr. Terence Ching discusses his journey into the field an...
Can Psychedelics Break the Consumption Cycle?
Consumer culture doesn’t just shape what we buy — it shapes what we want. Here’s why that’s harder to escape than you...
Psychedelics Can Just Be for Fun
Welcome to the Psychedelic Blog. I write about the impact of Psychedelics on Grieving, Relationships, Culture & Death.